Company intelligence / Profile preview
GB Sciences
Las Vegas, Nevada, United Statesgbsciences.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Phase 2
01
Overview
Achieved statistically significant results in Animal Proof-of-Concept Study for Parkinson's disease therapeutics. Received US Patent in 2020. Achieved positive proof-of-concept results for therapies designed to suppress COVID-Related Hyperinflammation in 2021. Recently signed licensing deal with EndoPure Life Sciences for their cannabinoid-based Parkinson's drug.
- Therapeutic areas
- PsychiatryNeurologyInfectious DiseasesCardiovascular
- Modalities
- Plant-inspired synthetic compoundsCannabinoid-based therapeutics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
EndoPure Life Sciences
Beyond the preview
Go deeper on GB Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB Sciences.